Trends in Formulation 2023
Read the article:
Read the eBook:
Feature|Articles|October 15, 2023
- Trends in Formulation, October 2023 eBook
- Volume 2023 eBook
- Issue 5
- Pages: 12-14
Trends in Formulation for Highly Potent Drugs
Author(s)Jill Murphy
When considering manufacturing and the growth of drug formulation, it is evident that there has been change and many new advancements introduced to make processes more efficient.
Advertisement
When considering manufacturing and the growth of drug formulation, it is evident that there has been change and many new advancements introduced to make processes more efficient. However, in terms of formulating highly potent drugs, their specific release requirements and poor aqueous bioavailability make them challenging to produce and analyze (1).
Although there may be difficulties seen with analytical challenges, the strength of oral solid dosage (OSD) forms and the manufacture of all pharmaceutical finished dosage forms continues to be prominent. According to research, the OSD market outlook is expected to continue growing and have low production costs, even with the knowledge of how unpredictable formulation may become (2).
Pharmaceutical Technology® discussed new formulation trends with Shailesh Vengurlekar, senior VP of Quailty and Regulatory Affairs at LGM Pharma, and how the industry can go forward with these advancements, despite any challenges that may arise.
About the author
Jill Murphy is Editor at Pharmaceutical Technology.
Article details
Pharmaceutical Technology
eBook: Trends in Formulation
October 2023
Pages: 12-14
Citation
When referring to this article, please cite it as J. Murphy, "Trends in Formulation for Highly Potent Drugs," Pharmaceutical Technology's Trends in Formulation eBook (October 2023).
Articles in this issue
almost 3 years ago
Advancing Oral Drug Development Using MIFDalmost 3 years ago
Optimizing the Total Cost of Ownership for APIsalmost 3 years ago
The New Digital Era for Formulation Developmentalmost 3 years ago
Innovative Start-Ups at CPHI Barcelonaalmost 3 years ago
Welcome to CPHI Barcelonaalmost 3 years ago
The Impact of AI on PharmaAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
PharmTech AI Pulse Check: On-Prem vs. Cloud AI
4
What the Olanzapine Depot Approval Means for CMC Teams
5